Modern says its COVOID-19 vaccine is more than 94% effective” This positive interim analysis from a Phase 3 study gave us the first clinical recognition that our vaccine can prevent COVID-19 disease, including critical illness,” said Stephen Bansell, CEO of Modern.
American biotech firm Modern on Monday announced its experimental vaccine against covid-19, which was 94.5 percent effective, the second major success in vaccine hunting.
Moderns released preliminary results from a clinical trial with more than 30,000 participants, with US pharmaceutical company Pfizer and its German partner BioNotech last week saying their vaccine was 90 percent effective.
Both vaccine frontrunners are based on a new platform called Messenger RNA, which generates faster than conventional vaccines and effectively transforms human cells into vaccine factories.
“This positive interim analysis from a Phase 3 study gave us the first clinical recognition that our vaccine can prevent COVID-19 disease, including critical illness,” said Stephen Bansell, CEO of Modern.
The company plans to submit an application for emergency approval in the US and around the world within weeks, and says it expects to have about 20 million doses ready to ship in the US by the end of the year.
Global infection from covid-19 has increased from 1.3 million to more than 54 million since the virus emerged at the end of last year in China.
The modern vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and preliminary results are based on 95 volunteers from 30,000 who fell ill with covid-19.
90 of the 95 were in the tested placebo group, and the five groups that received the drug are called mRNA-1273.
There were 11 people who fell seriously ill, all of whom were in the Plesibo group.
The vaccine was well tolerated, with most of the side effects classified as mild or moderate.
After the first dose, approximately three percent of people were classified as having severe injection site pain.
Among the serious side effects after the second dose, about 10 percent had fatigue, nine percent had muscle pain, five percent had joint pain or headache, four percent had other pain and two percent had redness at the injection site.
According to a statement, these adverse events were “short-lived”.
Peter Openshaw, professor of experimental medicine at Imperial College London, said, “This news of Modern is quite exciting and it gives rise to optimism that we will have a choice of good vaccines in the next few months.”
Critically, Modern also announced that its vaccine could remain stable at standard refrigerator temperatures of 2 ° C to 8 ° C (36 ° F to 46 ° F) for 30 days.
The company said that it can be kept in long-term storage at standard freezer temperatures of -20 ° C (-4 ° F) for up to six months.
Pfizer vaccines, on the other hand, need to be stored in deep-freezer conditions, which can complicate supply chain logistics, especially in less developed countries.
It is not yet clear how long protection from the Morden or Pfizer vaccine will last, nor how well they work for the most at-risk elderly, age group from covid-19.
COVOID-19 vaccine finally out now as Moderna Says Its COVID-19 Vaccine Is Over 94% Effective | video
Video by : CNBC Television